The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)
Publications
Churg-Strauss syndrome and the leukotriene receptor antagonist pranlukast.
Clinical rheumatology. 2005;24(6):661-2
Churg-Strauss syndrome (CSS) in a patient receiving pranlukast.
Clinical rheumatology. 2003;22(6):491-2
The Churg-Strauss syndrome after pranlukast treatment in a patient not receiving corticosteroids.
Annals of internal medicine. 2003;139(5 Pt 1):386-7
Churg-Strauss syndrome may be induced by leukotriene modifiers in severe asthma.
Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology. 2003;91(1):98
Churg-Strauss syndrome after reduction of inhaled corticosteroid in a patient treated with pranlukast for asthma.
Internal medicine (Tokyo, Japan). 2001;40(5):432-4
Leukotriene modifiers and Churg-Strauss syndrome: adverse effect or response to corticosteroid withdrawal?
Drug safety. 1999;21(4):241-51
Churg-Strauss syndrome after corticosteroid withdrawal in an asthmatic patient treated with pranlukast.
The Journal of allergy and clinical immunology. 1999;103(3 Pt 1):534-5